Vir Biotechnology EV/EBIT VIR

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2022.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 1.1×; May 2023
Peer median: 17.8×

Vir Biotechnology has no meaningful EV/EBIT today: it made an operating loss of $280.2M over the last twelve months.

It was last meaningful in May 2023, at 1.1×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	1.1×	0.6×	1.4×
2022	0.8×	0.3×	7.2×

Against its peers

Companies in Biotechnology nearest Vir Biotechnology's size, closest first, today.

Company	EV/EBIT
VIRVir Biotechnology	n/m
VCELVericel	116×
ADMAAdma Biologics	10.9×
MGTXMeiraGTx	4.6×
KRYSKrystal Biotech	42.4×
RGENRepligen	160×
TECHBIO-TECHNE	44.9×
HALOHalozyme Therapeutics	17.4×
NBIXNeurocrine Biosciences	18.2×
PLXProtalix BioTherapeutics	7.5×
EXELExelixis	15.4×
Peer median	17.8×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Vir Biotechnology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.